Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementGlobeNewsWire • 04/29/24
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)GlobeNewsWire • 04/17/24
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerGlobeNewsWire • 03/27/24
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)GlobeNewsWire • 03/25/24
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/08/24
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorGlobeNewsWire • 12/12/23
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion DiagnosticGlobeNewsWire • 12/05/23
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) TechnologyAccesswire • 09/14/23
PLOS ONE Publishes Data on Allarity Therapeutics' DRP® Companion Diagnostic for DovitinibGlobeNewsWire • 08/30/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/02/23
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion DiagnosticsGlobeNewsWire • 07/31/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/31/23
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology ExecutivesGlobeNewsWire • 07/24/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/20/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/19/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/13/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/11/23